IN8bio
INAB
26 hedge funds and large institutions have $2.06M invested in IN8bio in 2024 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.04% less ownership
Funds ownership: 0.58% → 0.54% (-0.04%)
70% less capital invested
Capital invested by funds: $6.77M → $2.06M (-$4.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$459K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$152K |
| 3 |
VF
Virtu Financial
New York
|
+$31.9K |
| 4 |
Jane Street
New York
|
+$17.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$274K |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$175K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$124K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$87.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$59K |
INAB Hedge Fund Activity: Q3 2024 in Review
26 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q3 2024, worth a combined $2.06M — down 70% from $6.77M a quarter earlier.
Fund positioning in INAB was balanced in Q3 2024: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 6 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $459K. The largest seller was AIGH Capital Management, cutting an estimated $274K.
- 26 institutional investors held IN8bio (INAB) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $2.06M of IN8bio stock for Q3 2024, down 70% quarter-over-quarter.
- 5 funds opened new IN8bio positions in Q3 2024 and 5 closed out, a net change of 0 holders.
- The largest IN8bio buyer in Q3 2024 was 683 Capital Management, an estimated $459K added.
- The largest IN8bio seller in Q3 2024 was AIGH Capital Management, an estimated $274K sold.
Based on aggregated 13F filings for Q3 2024.